Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04155047 · ClinicalTrials.gov registry record · Phase 4
A Clinical Study to Investigate if a Single Dose of an Approved Drug Product (Glycopyrrolate Inhalation Solution) Reduces Trapped Air in the Lungs of Participants With Chronic Obstructive Pulmonary Disease.
A Phase 4 study of Chronic Obstructive Pulmonary Disease (COPD), sponsored by Sunovion Respiratory Development.
- Completed
- Registry status
- Phase 4
- Development phase
- 44
- Enrollment target
- 1
- Study location
NCT04155047: Completed Phase 4 study of Chronic Obstructive Pulmonary Disease (COPD), sponsored by Sunovion Respiratory Development.
NCT04155047 is a Phase 4 study of Chronic Obstructive Pulmonary Disease (COPD) that has completed, run by Sunovion Respiratory Development. The registered enrollment target is 44 participants, below the 650-participant average among 36 other Chronic Obstructive Pulmonary Disease (COPD) trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04155047, a Phase 4 study of Chronic Obstructive Pulmonary Disease (COPD), has completed, sponsored by Sunovion Respiratory Development.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 44 participants
- Enrollment target
- 1
- Study location
Study Summary
A clinical study to investigate if a single dose of an approved drug product (glycopyrrolate Inhalation Solution) reduces trapped air in the lungs of participants with chronic obstructive pulmonary disease. This study is accepting male and female participants over the age of 40. The study will be conducted at one site located in the United States.
Primary Outcome
Change from baseline in Residual Volume (Residual Volume is defined as the volume of gas that remains in lungs after maximal exhalation) at 6 hours postdose.
Conditions Studied
Interventions
- COMBINATION_PRODUCT Glyocopyrrolate Inhalation Solution administered by Magnair
- DRUG Placebo administered by Magnair
Study Locations (1)
Missouri
- Midwest Chest Consultants - Saint Charles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2019-11-07 |
| Est. Completion | 2020-03-31 |
| Phase | Phase 4 |
What the finished NCT04155047 record still lists
NCT04155047 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 650-participant average among 36 other Chronic Obstructive Pulmonary Disease (COPD) trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Chronic Obstructive Pulmonary Disease (COPD) appearing as the primary indexed condition, and to 2 interventions - of which Glyocopyrrolate Inhalation Solution administered by Magnair is the first listed.
NCT04155047 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT04155047 about?
NCT04155047 is a clinical study titled "A Clinical Study to Investigate if a Single Dose of an Approved Drug Product (Glycopyrrolate Inhalation Solution) Reduces Trapped Air in the Lungs of Participants With Chronic Obstructive Pulmonary Disease.". A clinical study to investigate if a single dose of an approved drug product (glycopyrrolate Inhalation Solution) reduces trapped air in the lungs of participants with chronic obstructive pulmonary disease. This study is accepting male and female participants over the age of 40. The study will be co...
What is the current status of trial NCT04155047?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 44 participants. The study started on 2019-11-07. Estimated completion is 2020-03-31.
What conditions does trial NCT04155047 study?
This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease (COPD).
What interventions are being tested in trial NCT04155047?
The interventions under investigation include: Glyocopyrrolate Inhalation Solution administered by Magnair (COMBINATION_PRODUCT), Placebo administered by Magnair (DRUG).
Who is sponsoring clinical trial NCT04155047?
This trial is sponsored by Sunovion Respiratory Development, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04155047 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Obstructive Pulmonary Disease (COPD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04155047's enrollment target sits among peer trials
44 34th of 36 higher than 3 of 36 other Chronic Obstructive Pulmonary Disease (COPD) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Obstructive Pulmonary Disease (COPD) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Adherence Study in COPD Patients
COMPLETED · Phase 4
-
Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies
RECRUITING
-
Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD
RECRUITING · Phase 2
-
Multi-Center Clean Air Randomized Controlled Trial in COPD
RECRUITING · Phase 3
-
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI